Yuanguji is a clinical overall solution provider for respiratory infections. The company focuses on the respiratory infection track and provides molecular testing (including but not limited to mNGS, second-generation, and third-generation sequencing), including testing, products, equipment, Total clinical solutions for respiratory infections in the whole process of technology, interpretation, consultation, scientific research, drugs, and treatment. Recently, Yuanguji announced the latest financing progress, and signed a new round of capital increase agreement with National Science and Technology Yangtze River Delta Capital, Danlu Capital, and Gathering New Star Fund, and the old shareholder Danlu Capital continued to invest more. The investment is mainly used for Yuanguji to focus on the construction of respiratory specialty, to promote the transformation of production, education and research, and to create solutions for the whole life cycle of respiratory diseases.
This article is reproduced from: https://www.itjuzi.com/investevent/13413963
This site is for inclusion only, and the copyright belongs to the original author.